OPUS GENETICS INC
IRDNASDAQ🏆 #2630 by market capUS Equity
$851.84▲ $27.86 (+3.27%)
Simulated price1h—
24h▲ 3.3%
7d—
14d—
30d—
1y—
🏦Market Cap
$323M
Small Cap
📈Revenue Growth (YoY)
-12.2%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
25.4x
Expensive
Otter Score
59
Weak
No chart data available for IRD.
Trading Snapshot
- Day Range
- $845.82 – $860.77
- 52-Week Range
- $1.04 – $5.81
- Volume
- $3.82B
- Avg Volume
- $4.11B
- Shares Outstanding
- 82.6M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $13M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- 25.4x
- EPS (TTM)
- $-1.32
- Dividend Yield
- —
Why Investors Own IRD
- ✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$13M▲ +27.2% YoY
Gross Margin (TTM)
76.7%▲ +0.9% YoY
Operating Income (TTM)
$2M▲ +27.2% YoY
Free Cash Flow (TTM)
$1M▲ +27.2% YoY
About OPUS GENETICS INC
A company profile for OPUS GENETICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
59/100
Analyst Price Target
ⓘAverage Target
$1,015.26
▲ +19.2% Upside
High Target$1,187.62
Low Target$931.50
Based on 17 analysts
Latest News & Updates
🚀
Reuters·2h ago
OPUS GENETICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift IRD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
OPUS GENETICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.